[Key Financial Data](index=2&type=section&id=Item%201.%20Key%20Financial%20Data) [Core Financial Indicators](index=2&type=section&id=Item%20%281%29.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In Q1 2023, the company achieved robust performance with **$201 million** in operating revenue and **$27.67 million** in net profit attributable to shareholders, alongside positive operating cash flow and stable financial health | Indicator | Current Period | Prior Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue ($) | 200,800,387.47 | 157,604,605.75 | 27.41% | | Net Profit Attributable to Shareholders ($) | 27,669,629.76 | 20,258,223.51 | 36.58% | | Net Cash Flow from Operating Activities ($) | 505,655.16 | -4,394,061.58 | 111.51% | | Basic Earnings Per Share ($/share) | 0.3945 | 0.3851 | 2.44% | | **Balance Sheet Indicators** | **End of Current Period** | **End of Prior Year** | **Change from Year-End** | | Total Assets ($) | 1,431,675,016.45 | 1,406,080,553.60 | 1.82% | | Total Equity Attributable to Shareholders ($) | 1,180,672,946.34 | 1,153,003,316.58 | 2.40% | [Non-Recurring Gains and Losses Analysis](index=2&type=section&id=Item%20%282%29.%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Total non-recurring gains and losses for the period amounted to **$1.876 million**, positively impacting current net profit, primarily comprising **$1.174 million** in government grants and **$1.066 million** in investment income from transactional financial assets | Item | Amount for Current Period ($) | | :--- | :--- | | Gains and Losses from Disposal of Non-Current Assets | -41,203.90 | | Government Grants | 1,174,435.23 | | Gains and Losses Related to Transactional Financial Assets | 1,065,912.13 | | Other Non-Operating Income and Expenses | 10,073.57 | | Less: Income Tax Impact | 332,789.22 | | **Total** | **1,876,427.81** | [Reasons for Changes in Key Financial Indicators](index=2&type=section&id=Item%20%283%29.%20Changes%20and%20Reasons%20for%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The growth in key profit indicators for the period is primarily attributed to increased operating revenue, while the significant improvement in operating cash flow (up 111.51%) resulted from increased sales collections, indicating enhanced core business cash generation - The increase in net profit attributable to shareholders (up **36.58%** year-over-year) and non-recurring net profit (up **30.49%** year-over-year) was primarily due to increased operating revenue[8](index=8&type=chunk) - Net cash flow from operating activities increased by **111.51%** year-over-year, turning positive, primarily due to increased sales collections[9](index=9&type=chunk) [Shareholder Information](index=3&type=section&id=Item%202.%20Shareholder%20Information) [Shareholder Ownership Structure](index=3&type=section&id=Item%20%281%29.%20Total%20Number%20of%20Common%20Shareholders%2C%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Holdings) As of the end of the reporting period, the company had **10,849** common shareholders, with a concentrated equity structure where the top four shareholders are related parties collectively holding over **65%** of shares, and the actual controllers Xue Yongxin, Xue Yongjiang, Xue Gang, and Xue Weihong indirectly control **67.23%** of the company's equity through concerted action agreements - The total number of common shareholders at the end of the reporting period was **10,849**[10](index=10&type=chunk) - The company's actual controllers, Xue Yongxin, Xue Yongjiang, Xue Gang, and Xue Weihong, indirectly control **67.23%** of the company's equity through Enwei Group, Chengdu Jiewei, Chengdu Ruijinheng, Chengdu Zehong, and Changdu Jieweite, forming a concerted action group[10](index=10&type=chunk) - The largest shareholder, Chengdu Enwei Investment (Group) Co., Ltd., holds **28.64%** of the company's shares, with a portion (**4.5 million** shares) pledged[10](index=10&type=chunk) [Other Significant Matters](index=4&type=section&id=Item%203.%20Other%20Significant%20Matters) [Other Significant Matters](index=4&type=section&id=Item%203.%20Other%20Significant%20Matters) During the reporting period, the company had no other significant matters requiring disclosure - The company had no other applicable or significant matters to explain during this reporting period[12](index=12&type=chunk) [Quarterly Financial Statements](index=4&type=section&id=Item%204.%20Quarterly%20Financial%20Statements) [Consolidated Balance Sheet](index=4&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of March 31, 2023, the company's total assets were **$1.432 billion**, up 1.82% from the beginning of the year with a stable asset structure, while total liabilities slightly decreased to **$251 million**, and shareholders' equity increased by 2.40% to **$1.181 billion**, primarily due to accumulated current period profits | Item | End of Period Balance ($) | Beginning of Year Balance ($) | | :--- | :--- | :--- | | **Total Assets** | **1,431,675,016.45** | **1,406,080,553.60** | | Total Current Assets | 987,194,143.53 | 957,287,374.17 | | Total Non-Current Assets | 444,480,872.92 | 448,793,179.43 | | **Total Liabilities** | **251,002,070.11** | **253,077,237.02** | | **Total Shareholders' Equity** | **1,180,672,946.34** | **1,153,003,316.58** | [Consolidated Income Statement](index=6&type=section&id=2.%20Consolidated%20Income%20Statement) In Q1 2023, the company achieved total operating revenue of **$201 million**, a 27.41% year-over-year increase, with operating costs up 24.8%, selling expenses up 36.3%, and R&D expenses significantly increasing by 124.8%, ultimately resulting in a net profit attributable to parent company shareholders of **$27.67 million**, up 36.58% | Item | Amount for Current Period ($) | Amount for Prior Period ($) | | :--- | :--- | :--- | | **I. Total Operating Revenue** | **200,800,387.47** | **157,604,605.75** | | **II. Total Operating Costs** | **168,140,196.62** | **134,049,118.32** | | Selling Expenses | 59,019,548.45 | 43,296,237.94 | | Research and Development Expenses | 2,127,675.84 | 946,766.85 | | **III. Operating Profit** | **34,137,438.81** | **23,128,821.52** | | **V. Net Profit** | **27,669,629.76** | **20,258,223.51** | [Consolidated Cash Flow Statement](index=7&type=section&id=3.%20Consolidated%20Cash%20Flow%20Statement) In Q1 2023, the company's cash flow significantly improved, with net cash flow from operating activities turning positive at **$0.506 million** from -$4.394 million in the prior year, and net cash flow from investing activities at **$22.06 million** primarily due to cash received from investment-related activities, increasing the period-end cash and cash equivalents balance to **$364.12 million** | Item | Amount for Current Period ($) | Amount for Prior Period ($) | | :--- | :--- | :--- | | **Net Cash Flow from Operating Activities** | **505,655.16** | **-4,394,061.58** | | **Net Cash Flow from Investing Activities** | **22,062,212.40** | **-11,212,372.79** | | **Net Cash Flow from Financing Activities** | **0.00** | **-352,000.00** | | **Net Increase in Cash and Cash Equivalents** | **22,541,970.22** | **-15,966,410.88** | | **End of Period Cash and Cash Equivalents Balance** | **364,120,291.46** | **48,283,675.61** | [Audit Information](index=9&type=section&id=Item%20%282%29.%20Audit%20Report) The company's Q1 2023 financial report was unaudited - The company's first-quarter report was unaudited[21](index=21&type=chunk)

证券代码：301331 证券简称：恩威医药 公告编号：2023-007 恩威医药股份有限公司 关于举行 2022 年度暨 2023 年一季度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 欢迎广大投资者积极参与本次网上说明会。 特此公告。 恩威医药股份有限公司董事会 2023 年 4 月 22 日 恩威医药股份有限公司（以下简称"公司"）定于 2023 年 5 月 8 日（星期一）下午 15：00-17：00 在全景网举办 2022 年度暨 2023 年一季度业绩网上说明会，本次年度业 绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长兼首席执行官薛永江、财务负责人兼董事会 秘书胡大伟、独立董事冯建、保荐代表人石坡。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度暨 2023 年一季度业绩 网上说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 8 日（星期一 ...